Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom Large; J&J Seeks Spravato Monotherapy Approval; Canadian Study to Parse Out Role of Psychotherapy

Google co-founder and psychedelics dabbler Sergey Brin looks set to fill $15M of a $25M round by ibogaine biotech Soneira Bio, which hopes to develop the drug for traumatic brain injury (TBI). Murmurings of the startup and its potential suitors have been doing the rounds for more than a year, with excitement abounding among the likes of the Jurvetsons and Brin. Sign-in or join Pα+ to…

Source